Cefamandole: in vitro and clinical pharmacokinetics
- PMID: 1008540
- PMCID: PMC429842
- DOI: 10.1128/AAC.10.5.814
Cefamandole: in vitro and clinical pharmacokinetics
Abstract
Cefamandole has a broader spectrum and greater potency than the other cephalosporins. It includes Haemophilus influenzae, most strains of Enterobacter, and many strains of indole-positive Proteus and Bacteroides, with a lower minimal inhibitory concentration for Escherichia coli, Klebsiella, etc. Concentrations of drug in the serum after the parenteral injection of cefamandole exceed manyfold the minimal inhibitory concentrations of over 82% of the bacteria studied. Approximately 65 to 85% is excreted in a biologically active form in the urine. This antibiotic offers advantages of antibacterial effectiveness and at the same time retains the safety of penicillin G and cephalothin in animals.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources